Clinical Trials Logo

Filter by:
  • Terminated  
  • Page [1]
NCT ID: NCT01745367 Terminated - Clinical trials for Triple Negative Breast Cancer

Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

BATON-BC
Start date: November 2012
Phase: Phase 2
Study type: Interventional

This is a phase 2 multicenter, double-blind, randomized, placebo-controlled, two-arm study for subjects with locally recurrent or metastatic triple negative breast cancer.

NCT ID: NCT00517192 Terminated - HIV Infections Clinical Trials

Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI

Start date: September 2007
Phase: Phase 3
Study type: Interventional

The objective of this study is to compare the efficacy and safety of Tipranavir/ritonavir (TPV/r, 500mg/200mg twice daily) to the safety and efficacy of Darunavir/ritonavir (DRV/r 600 mg /100 mg twice daily) in combination with investigator selected optimised background regimens in patients who are three-class (Nucleoside reverse transcriptase inhibitors (NRTI), Nonnucleoside reverse transcriptase inhibitors (NNRTI), and Protease inhibitor (PI)) treatment-experienced (a minimum of 3-months duration for each class) with resistance to more than one PI on the screening virtual phenotype resistance testing.

NCT ID: NCT00144105 Terminated - HIV Infections Clinical Trials

A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.

Start date: February 2004
Phase: Phase 2
Study type: Interventional

Evaluation of safety and efficacy of Tipranavir (TPV) boosted with Ritonavir (RTV) versus an active control arm (Lopinavir / RTV) in antiretroviral (ARV) therapy naïve HIV-1 infected patients